Page last updated: 2024-08-21

indazoles and snx 2112

indazoles has been researched along with snx 2112 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bauer, TM; Bendell, JC; Burris, HA; Hinson, JM; Infante, JR; Jones, S; Orlemans, EO; Ramanathan, RK; Tibes, R; Von Hoff, DD; Weiss, GJ	1

Trials

1 trial(s) available for indazoles and snx 2112

Article	Year
Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:17 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Benzamides; Biological Availability; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glycine; Heterocyclic Compounds, 4 or More Rings; HSP90 Heat-Shock Proteins; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prodrugs; Vision Disorders	2014

Article

Year

Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.

European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:17

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Benzamides; Biological Availability; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glycine; Heterocyclic Compounds, 4 or More Rings; HSP90 Heat-Shock Proteins; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prodrugs; Vision Disorders

2014